NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,
SALE OF ALTRAN'S SHARES BY APAX PARTNERS AND ALTAMIR
PARIS, June 22, 2017 - Apax Partners and Altamir announce the successful sale by their subsidiary Altrafin Participations SAS ("Altrafin") of 14,796,677 Altran Technologies SA ("Altran") shares, representing 8.4% of the share capital, at a price of 15.0 euros per share (i.e., an amount of 222 million euros) by way of an accelerated bookbuilding involving institutional investors (the "Offering").
The Offering including shares sold by Altrafin and by founding shareholders of Altran part of the concert group (such shareholders, together with Altrafin, the "Selling Shareholders") amounted to 19,774,313 shares, representing 11.2% of Altran share capital. It was completed at a price of 15.0 euros per share (i.e., a total amount of 297 million euros).
Following this transaction, Apax and Altamir will hold, through their subsidiary Altrafin, 14,796,677 shares in Altran, representing 8.4% of the share capital.
This press release does not constitute an offer to sell, and the offer of Altran shares by the Selling Shareholders does not constitute a public offering.
About Apax Partners
Apax Partners is a leading private equity firm in French-speaking countries in Europe. With more than 45 years of experience, Apax Partners provides long-term equity financing to build and strengthen world-class companies. Funds managed and advised by Apax Partners exceed €3 billion. These funds invest in fast-growing middle-market companies across four sectors of specialisation:
TMT: Altran, Gfi Informatique, InfoVista, Melita, Nowo-ONI and Vocalcom
Consumer: Europe Snacks, Groupe AFFLELOU, Groupe Royer, Sandaya, and THOM Europe (Histoire d'Or, Marc Orian, TrésOr, Stroili and Oro Vivo)
Healthcare: Amplitude Surgical
Services: Groupe INSEEC, Marlink and SK FireSafety
Altamir (Euronext Paris-B, LTA) is a listed private equity company with almost €800m in assets under management. The company invests via and with the funds managed or advised by Apax Partners France and Apax Partners LLP, two leading private equity firms in their respective markets. It provides access to a diversified portfolio of fast-growing companies across Apax's sectors of specialisation (TMT, Retail & Consumer, Healthcare, Business & Financial Services) and in complementary market segments (mid-sized companies in French-speaking European countries and larger companies across Europe, North America and key emerging markets).
Tel.: + 33 1 53 65 01 35
Email: [email protected]
Tel.: +33 1 53 65 01 74
Email: [email protected]
This press release is not an offer for sale of nor an invitation to purchase or to subscribe for securities in the United States or in any other jurisdiction. The securities may not be offered, subscribed for, pledged, sold or otherwise transferred in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and in compliance with any applicable state securities laws. The Altran shares have not been and will not be registered under the U.S. Securities Act and Altrafin does do not intend to undertake a public offering of Altran securities in the United States.
This press release does not, and shall not, in any circumstances, constitute an offer to the public of the Altran shares nor an invitation to the public in connection with any offer in any jurisdiction, including France. This press release does not constitute an advertisement or a prospectus within the meaning of Directive 2003/71/CE of the European Parliament and Council dated November 4, 2003, as amended, to the extent implemented in the relevant member states of the European Economic Area (together, the "Prospectus Directive"). The Altran shares cannot be offered and will not be offered in any Member State, except in accordance with the exemptions set out in Article 3(2) of the Prospectus Directive, if they have been implemented in the relevant Member State(s) or in the other cases which do not require the publication of a prospectus pursuant to the Prospectus Directive and/or applicable regulation in the Member States.
This information is provided by RNS